Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study

BACKGROUND AND AIMS: Pirfenidone (PFD), an oral antifibrotic drug, has been authorized by the EMA and FDA for treatment of idiopathic pulmonary fibrosis. Few studies have addressed its use in advanced liver fibrosis (ALF). We evaluated a prolonged-release formulation (PR-PFD) plus standard of care o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepatol Int
Main Authors: Poo, Jorge Luis, Torre, Aldo, Aguilar-Ramírez, Juan Ramón, Cruz, Mauricio, Mejía-Cuán, Luis, Cerda, Eira, Velázquez, Alfredo, Patiño, Angélica, Ramírez-Castillo, Carlos, Cisneros, Laura, Bosques-Padilla, Francisco, Hernández, Larissa, Gasca, Frida, Flores-Murrieta, Francisco, Treviño, Samuel, Tapia, Graciela, Armendariz-Borunda, Juan, Muñoz-Espinosa, Linda E.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer India 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7561536/
https://ncbi.nlm.nih.gov/pubmed/32813194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12072-020-10069-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados